Interaksi Triheksifenidil

Avoid administrations of TUDORZA PRESSAIR with other anticholinergic-containing drugs. (label Aklidinium, Interaksi obat)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Usage of MOTOFEN ® in recommended doses is not likely to cause prominent anticholinergic side effects, but MOTOFEN ® should be avoided in patients in whom anticholinergic drugs are contraindicated. (label Difenoksin dan atropin, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

• Other Conditions Exacerbated by Anticholinergic Adverse Reactions : Use is not recommended in patients with autonomic neuropathy, hyperthyroidism, cardiac disease, hiatal hernia, etc. (label Glikopironium, Peringatan dan perhatian)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (label Ipratropium, Interaksi obat)

In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. (label Kalium sitrat, Kontraindikasi)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent. (label Kuinidin, Kontraindikasi)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever, serotonin syndrome, and primary central nervous system pathology. (label Metoklopramid, Peringatan dan perhatian)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (label Rivastigmin, Interaksi obat)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (label Tiotropium, Interaksi obat)

…(HR) b or Serotonin Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension… (label Tranilsipromin, Interaksi obat)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Avoid administration of Umeclidinium ELLIPTA with other anticholinergic-containing drugs. (label Umeklidinium, Interaksi obat)

Avoid administration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs. (label Umeklidinium dan vilanterol, Interaksi obat)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (label Triheksifenidil, Peringatan)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See DOSAGE AND ADMINISTRATION ). (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. (label Triheksifenidil, Peringatan)

Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. (label Triheksifenidil, Peringatan)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drugs that alter gastrointestinal motility: The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. (label Benazepril dan hidroklorotiazid, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Darifenacin extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as severe constipation, ulcerative colitis, and myasthenia gravis. (label Darifenasin, Peringatan dan perhatian)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Anticholinergic effects of quinidine: Monitor for worsening in myasthenia gravis and other sensitive conditions. (label Dekstrometorfan dan kuinidin, Peringatan dan perhatian)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (label Deutetrabenazin, Peringatan dan perhatian)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. (label Triheksifenidil, Peringatan)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Anticholinergic agents: may affect the gastrointestinal absorption of various drugs; may also increase certain actions or side effects of other anticholinergic drugs (7) (label Disikloverin, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. (label Triheksifenidil, Peringatan)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Urinary Retention in Adult Patients With Bladder Outlet Obstruction The use of Toviaz, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction, including patients with urinary retention, may result in further urinary retention and kidney injury. (label Fesoterodin, Peringatan dan perhatian)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Because of its anticholinergic effects, XEOMIN should be used with caution in patients at risk of developing narrow angle glaucoma. (label IncobotulinumtoxinA, Peringatan dan perhatian)

Caution is, therefore, advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution with other drugs having anticholinergic properties. β-adrenergic agents Caution is advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution and other sympathomimetic agents due to the increased risk… (label Ipratropium dan salbutamol, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (label Karbidopa, Peringatan)

The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See DOSAGE AND ADMINISTRATION ). (label Triheksifenidil, Interaksi obat)

The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See DOSAGE AND ADMINISTRATION ). (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See DOSAGE AND ADMINISTRATION ). (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

• Urinary Retention in Patients With Bladder Outlet Obstruction and in Patients Taking Muscarinic Antagonist Drugs for Overactive Bladder : Administer with caution in these patients because of risk of urinary retention. (label Mirabegron, Peringatan dan perhatian)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

An anticholinergic agent, (e.g., atropine sulfate or glycopyrrolate) should be administered prior to Neostigmine Methylsulfate Injection administration to lessen the risk of bradycardia [ see Dosage and Administration ( 2.4 ) ]. (label Neostigmin, Peringatan dan perhatian)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Oxybutynin chloride extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis and intestinal atony. (label Oksibutinin, Peringatan dan perhatian)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Anticholinergic Drugs Use of anticholinergic drugs after administration of BOTOX may potentiate systemic anticholinergic effects. (label OnabotulinumtoxinA, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). (label Pilokarpin, Interaksi obat)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (label Piridostigmin, Peringatan dan perhatian)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Anticholinergic drugs administered concurrently with PA may produce additive antivagal effects on A-V nodal conduction, although this is not as well documented for PA as for quinidine. (label Prokainamid, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Urinary Retention The use of Solifenacin succinate tablets, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction including patients with urinary retention, may result in further urinary retention and kidney injury. (label Solifenasin, Peringatan dan perhatian)

Monitor for hemodynamic changes and administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. (label Sugamadeks, Peringatan dan perhatian)

Pretreatment with anticholinergic agents (e.g., atropine) may reduce the occurrence of bradyarrhythmias. (label Suksinilkolin, Peringatan dan perhatian)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (label Toksin botulinum tipe A, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

The recent use of other drugs that cause CNS depression or EPS symptoms (e.g., alcohol, sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics) may also increase the risk for these serious CNS reactions [see Warnings and Precautions ( 5.1 , 5.5 )] . (label Trimetobenzamid, Peringatan dan perhatian)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Trospium chloride extended-release capsules, like other antimuscarinic agents, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis. (label Trospium, Peringatan dan perhatian)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (label Valbenazin, Peringatan dan perhatian)

Urinary Retention : Monitor for urinary retention, especially in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for OAB, in whom the risk of urinary retention may be greater. (label Vibegron, Peringatan dan perhatian)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (label Triheksifenidil, Interaksi obat)

When benztropine mesylate is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. (label Benztropin, Peringatan)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Donepezil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

NAMZARIC may interfere with anticholinergic medications. (label Memantin dan donepezil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly. (label Sevimelin, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

It is difficult to determine if Tolcapone tablets played a role in the pathogenesis of these events because these patients received several concomitant medications affecting the central nervous system such as monoaminergic (i.e., MAO-I, tricyclic and selective serotonin reuptake inhibitors) and anticholinergic agents. (label Tolkapon, Perhatian)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)